Eli Lilly Management Team

Eli Lilly: Big 2025 Ahead, But Execution Risks Exist

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click here to read why LLY is a Buy.

Business Insider · 1d

Eli Lilly sees growth in 2025 from new medicines

Lilly anticipates revenue growth contributions in 2025 from new Lilly medicines such as Jaypirca, Ebglyss, Omvoh and Kisunla; approvals of new

Yahoo · 16h

Eli Lilly: What's Left To Like? A Lot, Says One Analyst.

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

AOL · 1d

Eli Lilly stock down on Q4 guidance miss

Eli Lilly shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised it

Eli Lilly To Buy Scorpion Therapeutics' Experimental Cancer Therapy For Up To $2.5 Bln In Cash

Eli Lilly and Company (LLY) on Monday said it has agreed to buy Scorpion Therapeutics' experimental cancer therapy PI3Ka inhibitor ...

Eli Lilly Scoops Up Scorpion Therapeutics' Early-Stage Cancer Program For $2.5 Billion

Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its precision medicines pipeline.

Lilly to pay $2.5B for Boston biotech's lead cancer drug

Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now